Nyxoah (NASDAQ:NYXH) Trading Down 2.9% – Time to Sell?
by Doug Wharley · The Cerbat GemNyxoah SA (NASDAQ:NYXH – Get Free Report)’s stock price was down 2.9% during trading on Friday . The stock traded as low as $4.69 and last traded at $4.73. Approximately 24,570 shares changed hands during mid-day trading, a decline of 52% from the average daily volume of 51,594 shares. The stock had previously closed at $4.87.
Wall Street Analyst Weigh In
Several equities analysts recently issued reports on the stock. Piper Sandler reiterated an “overweight” rating and set a $9.00 price target (down previously from $12.00) on shares of Nyxoah in a research report on Friday, November 14th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Nyxoah in a research report on Monday, December 1st. Three investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $12.67.
Get Our Latest Stock Report on NYXH
Nyxoah Stock Performance
The company has a market capitalization of $161.10 million, a P/E ratio of -1.90 and a beta of 1.55. The company’s 50 day moving average is $5.26 and its 200-day moving average is $6.26. The company has a current ratio of 1.70, a quick ratio of 1.41 and a debt-to-equity ratio of 0.40.
Nyxoah (NASDAQ:NYXH – Get Free Report) last announced its earnings results on Friday, November 14th. The company reported ($0.74) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.61) by ($0.13). Nyxoah had a negative net margin of 1,457.97% and a negative return on equity of 101.99%. The business had revenue of $2.31 million for the quarter, compared to the consensus estimate of $1.95 million. Equities analysts anticipate that Nyxoah SA will post -1.91 EPS for the current fiscal year.
Institutional Investors Weigh In On Nyxoah
Several hedge funds have recently added to or reduced their stakes in NYXH. Kovack Advisors Inc. grew its stake in shares of Nyxoah by 148.2% in the second quarter. Kovack Advisors Inc. now owns 57,827 shares of the company’s stock worth $433,000 after acquiring an additional 34,532 shares during the last quarter. Franklin Resources Inc. boosted its stake in Nyxoah by 0.9% in the 2nd quarter. Franklin Resources Inc. now owns 294,990 shares of the company’s stock worth $2,207,000 after purchasing an additional 2,655 shares in the last quarter. Raymond James Financial Inc. purchased a new stake in Nyxoah during the 2nd quarter valued at about $70,000. Bank of America Corp DE increased its stake in Nyxoah by 72.4% during the 2nd quarter. Bank of America Corp DE now owns 7,866 shares of the company’s stock valued at $59,000 after purchasing an additional 3,303 shares in the last quarter. Finally, Shay Capital LLC purchased a new position in Nyxoah in the second quarter worth about $374,000.
Nyxoah Company Profile
Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea.